Safety and tolerability of anselamimab in participants with light chain amyloidosis: Results from a phase 2 study.
BACKGROUND: Light chain (AL) amyloidosis is a rare, potentially fatal plasma cell dyscrasia (PCD). Most common TEAEs were consistent with AL amyloidosis or anti-PCD therapy.
BACKGROUND: Light chain (AL) amyloidosis is a rare, potentially fatal plasma cell dyscrasia (PCD). Most common TEAEs were consistent with AL amyloidosis or anti-PCD therapy.
What the study was
- Study design
- Phase II Clinical Trial
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Eur J Cancer
Why it surfaced
Affirmative clinical guideline or practice recommendation language present; Phase II clinical trial; Topic: Rare diseases with high unmet need; Score 7/10 → STANDARD priority
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.